← All trials
NCT05805605
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2023
- Primary completion
- Oct 22, 2027
- Completion date
- Oct 22, 2028
- First posted
- Apr 10, 2023
- Last posted
- May 6, 2023
- Enrollment
- 56
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of MinnesotaLead sponsor
- University of MinnesotaOverall official - principal investigator
Drugs studied
Indications studied
- Burkitt Lymphoma
- Leukemia
- Leukemia, Myeloid
- Leukemia, Plasma Cell
- Lymphoma, Follicular
- Myelodysplastic Syndromes
- Myeloproliferative Disorders
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Biphenotypic, Acute
- Leukemia, Prolymphocytic
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid, Acute
- Lymphoma, T-Cell
- Lymphoma, B-Cell, Marginal Zone
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Primary Myelofibrosis
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.